Westphal Patrick Jacobsen, Teixeira Cassiano, Krauzer João Ronaldo Mafalda, Bueno Mirelle Hugo, Pereira Priscilla Alves, Hostyn Sandro V, Vieira Marcela Doebber, Durante Camila, Bündchen Cristiane
Hospital Moinhos de Vento - Porto Alegre (RS), Brazil.
Universidade Federal de Ciências da Saúde de Porto Alegre - Porto Alegre (RS), Brazil.
Crit Care Sci. 2025 Feb 17;37:e20250161. doi: 10.62675/2965-2774.20250161. eCollection 2025.
To identify predictive factors for failure in the installation of high-flow nasal cannulas in children diagnosed with acute viral bronchiolitis under 24 months of age admitted to the pediatric intensive care unit.
This work was a retrospective single-center cohort study conducted from March 2018 to July 2023 involving infants under 24 months of age who were diagnosed with acute viral bronchiolitis and who received high-flow nasal cannulas upon admission to the pediatric intensive care unit. Patients were categorized into two groups, the Success Group and Failure Group, on the basis of high-flow nasal cannula therapy efficacy. The primary outcome was treatment failure, which was defined as the transition to invasive or noninvasive ventilation. The analyzed variables included age, sex, weight, high-flow nasal cannula parameters, vital signs, risk factors, comorbidities, and imaging. Acute viral bronchiolitis severity was assessed using the Wood-Downes Scale, and functional status was assessed via the Functional Status Scale, both of which were administered by trained physiotherapists.
In total, 162 infants with acute viral bronchiolitis used high-flow nasal cannulas, with 17.28% experiencing treatment failure. The significant differences between the Failure and Success Groups included age (p = 0.001), weight (p = 0.002), bronchiolitis severity (p = 0.004), initial high-flow nasal cannula flow (p = 0.001), and duration of use (p = 0.000). The cutoff values for initial flow (≤ 12L/min), weight (≤ 5kg), and Wood-Downes score (≥ 9 points) were determined from the ROC curves. Initial flow ≤ 12L/min was the most predictive for failure (AUC = 0.71; 95%CI: 0.61 - 0.84; p = 0.001). Multivariate analysis indicated that weight was a protective factor (RR = 0.87; 95%CI: 0.78 - 0.98), duration of use reduced the risk of failure (RR = 0.49; 95%CI: 0.38 - 0.64; p = 0.000), and Wood-Downes score was not significant (RR = 1.04; 95%CI: 0.95 - 1.14; p = 0.427). Weight explained 84.7% of the variation in initial flow.
Risk factors for high-flow nasal cannula therapy failure in bronchiolitis patients include younger age, consequently lower weight, and a lower initial flow rate.
确定24个月以下诊断为急性病毒性细支气管炎并入住儿科重症监护病房的儿童,在使用高流量鼻导管时治疗失败的预测因素。
本研究为回顾性单中心队列研究,于2018年3月至2023年7月进行,纳入24个月以下诊断为急性病毒性细支气管炎且入住儿科重症监护病房时接受高流量鼻导管治疗的婴儿。根据高流量鼻导管治疗效果将患者分为两组,即成功组和失败组。主要结局为治疗失败,定义为转为有创或无创通气。分析的变量包括年龄、性别、体重、高流量鼻导管参数、生命体征、危险因素、合并症及影像学检查。急性病毒性细支气管炎严重程度采用Wood-Downes量表评估,功能状态通过功能状态量表评估,均由经过培训的物理治疗师进行评估。
共有162例急性病毒性细支气管炎婴儿使用了高流量鼻导管,其中17.28%治疗失败。失败组与成功组之间的显著差异包括年龄(p = 0.001)、体重(p = 0.002)、细支气管炎严重程度(p = 0.004)、初始高流量鼻导管流速(p = 0.001)及使用时间(p = 0.000)。通过ROC曲线确定了初始流速(≤12L/min)、体重(≤5kg)及Wood-Downes评分(≥9分)的截断值。初始流速≤12L/min对治疗失败的预测性最强(AUC = 0.71;95%CI:0.61 - 0.84;p = 0.001)。多因素分析表明,体重是保护因素(RR = 0.87;95%CI:0.78 - 0.98),使用时间可降低失败风险(RR = 0.49;95%CI:0.38 - 0.64;p = 0.000),而Wood-Downes评分无显著意义(RR = 1.04;95%CI:0.95 - 1.14;p = 0.427)。体重解释了初始流速变异的84.7%。
细支气管炎患者高流量鼻导管治疗失败的危险因素包括年龄较小、体重较低以及初始流速较低。